Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Holcombe Edwin Grier, M.D.

Co-Author

This page shows the publications co-authored by Holcombe Grier and Mark Gebhardt.
Connection Strength

1.248
  1. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer. 2015 Feb 01; 121(3):467-75.
    View in: PubMed
    Score: 0.148
  2. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009 May 20; 27(15):2536-41.
    View in: PubMed
    Score: 0.101
  3. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Dec; 49(7):894-900.
    View in: PubMed
    Score: 0.092
  4. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11.
    View in: PubMed
    Score: 0.076
  5. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol. 2005 Jun 20; 23(18):4031-8.
    View in: PubMed
    Score: 0.076
  6. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 20; 348(8):694-701.
    View in: PubMed
    Score: 0.066
  7. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol. 2002 Dec; 24(9):722-6.
    View in: PubMed
    Score: 0.065
  8. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 Jan 15; 20(2):426-33.
    View in: PubMed
    Score: 0.061
  9. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol. 2001 Aug-Sep; 23(6):340-8.
    View in: PubMed
    Score: 0.059
  10. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1154-61.
    View in: PubMed
    Score: 0.055
  11. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):486-93.
    View in: PubMed
    Score: 0.053
  12. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 03; 109:36-50.
    View in: PubMed
    Score: 0.050
  13. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol. 1998 Sep; 16(9):3021-7.
    View in: PubMed
    Score: 0.049
  14. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct; 17(10):1396-1408.
    View in: PubMed
    Score: 0.042
  15. Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Ann Surg Oncol. 2016 10; 23(11):3541-3547.
    View in: PubMed
    Score: 0.041
  16. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Jan; 63(1):54-61.
    View in: PubMed
    Score: 0.040
  17. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Sep; 51(3):334-8.
    View in: PubMed
    Score: 0.024
  18. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01; 26(4):633-8.
    View in: PubMed
    Score: 0.023
  19. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10; 25(5):501-6.
    View in: PubMed
    Score: 0.022
  20. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. J Clin Oncol. 2006 Aug 20; 24(24):3838-43.
    View in: PubMed
    Score: 0.021
  21. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 01; 24(1):152-9.
    View in: PubMed
    Score: 0.020
  22. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53.
    View in: PubMed
    Score: 0.017
  23. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg. 2003 Oct; 238(4):563-7; discussion 567-8.
    View in: PubMed
    Score: 0.017
  24. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003 Apr 15; 21(8):1574-80.
    View in: PubMed
    Score: 0.017
  25. Childhood soft tissue sarcoma: a 20-year experience. J Pediatr. 1997 Oct; 131(4):603-7.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.